Novo Nordisk Advances Amycretin for Weight Management to Phase 3

Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...
Home/KnloSights/Clinical Trial Updates/Novo Nordisk Advances Amycretin for Weight Management to Phase 3